Disease Indications: Leukemia, Bile Duct Cancer

Manufacturer: Agios Pharmaceuticals, Inc.

Usage: Oral

Medicine approved by:

Food and Drug Administration (FDA)

Tibsovo (ivosidenib) is designed to treat two conditions: relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation, and previously treated, locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with the same mutation.